Immunic (IMUX) Equity Average (2014 - 2026)

Immunic has disclosed Equity Average across 13 years of filings, most recently posting $72.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $72.3 million, up 999.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.3 million (up 999.98% YoY), and the FY2025 annual result was $5.9 million, down 75.18% from the prior year.
• Equity Average came in at $72.3 million for Q1 2026 at Immunic, up from $1.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $132.9 million in Q2 2022 to a low of $1.9 million in Q4 2025.
• The 5-year median for Equity Average is $58.8 million (2023), against an average of $65.0 million.
• Across the five-year window, Equity Average slumped 93.59% in 2025 and surged 999.98% in 2026, its largest moves.
• Immunic's Equity Average stood at $111.2 million in 2022, then slumped by 65.24% to $38.7 million in 2023, then decreased by 22.87% to $29.8 million in 2024, then plunged by 93.59% to $1.9 million in 2025, then surged by 3678.36% to $72.3 million in 2026.
• The last three Equity Average figures came in at $72.3 million (Q1 2026), $1.9 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.